AKT1 and neoplasm: Treatment with 4-Methylumbelliferone (4-MU), which inhibits HA synthases, blocked HA accumulation in the ECM, decreased CD44 activation, resulted in diminished PI3K, AKT, and ERK signaling, and led to proapoptotic, antiproliferative, and antimetastatic effects in cultured tumor cells [28,29,30,31].